Artal Group’s Acceleron Pharma XLRN Stock Holding History

Artal Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200,000	Closed	-$9.31M	–	124
2019 Q1	$9.31M	Hold	200,000	–	–	0.38%	54
2018 Q4	$8.71M	Buy	+200,000	New	+$9.99M	0.32%	51
2018 Q3	–	Sell	-100,000	Closed	-$4.85M	–	121
2018 Q2	$4.85M	Buy	+100,000	New	+$3.64M	0.1%	69

Artal Group's XLRN Position: Q4 2021 in Review

Artal Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,000,000 shares — an estimated $172M sold.

Artal Group first reported a position in XLRN in Q2 2016 and held it in 22 quarters. The position peaked at $190M in Q1 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Artal Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Artal Group sold 1,000,000 Acceleron Pharma shares in Q4 2021, an estimated $172M.
Artal Group first reported a position in Acceleron Pharma in Q2 2016 and held it in 22 quarters.
Artal Group's Acceleron Pharma position peaked at $190M in Q1 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.